HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
- 9 March 2020
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (5) , 529-537
Abstract
Combination antiretroviral therapy has transformed HIV-1 infection, once a fatal illness, into a manageable chronic condition. Drug resistance, severe side effects and treatment noncompliance bring challenges to combination antiretroviral therapy implementation in clinical settings and indicate the need for additional molecular targets. Here, we have identified several small-molecule fusion inhibitors, guided by a neutralizing antibody, against an extensively studied vaccine target—the membrane proximal external region (MPER) of the HIV-1 envelope spike. These compounds specifically inhibit the HIV-1 envelope-mediated membrane fusion by blocking CD4-induced conformational changes. An NMR structure of one compound complexed with a trimeric MPER construct reveals that the compound partially inserts into a hydrophobic pocket formed exclusively by the MPER residues, thereby stabilizing its prefusion conformation. These results suggest that the MPER is a potential therapeutic target for developing fusion inhibitors and that strategies employing an antibody-guided search for novel therapeutics may be applied to other human diseases.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (AI127193, AI129721, GM116898, GM116898, AI129721, AI112489, AI127193)
This publication has 56 references indexed in Scilit:
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120Proceedings of the National Academy of Sciences, 2012
- Pocketome: an encyclopedia of small-molecule binding sites in 4DNucleic Acids Research, 2011
- Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesNature Structural & Molecular Biology, 2010
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesProceedings of the National Academy of Sciences, 2008
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusionProceedings of the National Academy of Sciences, 2006
- Novel Therapies Based on Mechanisms of HIV-1 Cell EntryNew England Journal of Medicine, 2003
- NMRPipe: A multidimensional spectral processing system based on UNIX pipesJournal of Biomolecular NMR, 1995